Research programme: thyroid hormone receptor beta agonists - Karo Pharma
Alternative Names: KB-141Latest Information Update: 21 Dec 2016
At a glance
- Originator Karo Bio
- Class Phenyl ethers; Phenylacetates
- Mechanism of Action Thyroid hormone receptor beta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 06 May 2004 Bristol-Myers Squibb announced its decision to return rights to the lead compound to Karo Bio and discontinued internal development on this programme
- 06 May 2004 Preclinical trials in Obesity in Sweden (unspecified route)
- 23 Sep 2003 A preclinical study has been added to the Obesity pharmacodynamics section